The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis
CAR-T-cell therapy targeting the GD2 antigen is promising for treating NB. However, its efficacy is moderate, and treatment can lead to hematologic toxicities such as anemia, neutropenia, and thrombocytopenia, which require careful monitoring.
Authors
- Behrouz Robat-Jazi (ORCID: https://orcid.org/0000-0001-7366-0972)
- Mahsa Ahmadpour (ORCID: https://orcid.org/0009-0005-7908-0836)
- Negar Nejati (ORCID: https://orcid.org/0000-0002-8192-8542)
- Sajjad Ahmadpour
- Ali Zand
- Mohammad Amin Habibi
- Mohsen Dashti
- Parsa Lorestan
- Farzad Maleki
- Zahra Karimizadeh
- Alireza Khodadadiyan
Institutions
- Tabriz University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Islamic Azad University Medical Branch of Tehran (IR)
- Urmia University (IR)
- Kermanshah University of Medical Sciences (IR)
- Shariati Hospital (IR)
- Stem Cell Technology Research Center (IR)
- Faghihi Hospital (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1186/s40001-025-03764-0
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00